drugset / Trial / NCT00822237

Study to Test the Safety and Immunogenicity of VARIVAX (2007 Process) (Study V210-057) (Completed)

NCT00822237

Phase 3 Completed 598 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupTriple-blindPrevention

Summary

This study will test the safety, tolerability, and immunogenicity of VARIVAX manufactured with the 2007 commercial Varicella-Zoster Virus (VZV) bulk process when concomitantly administered with M-M-R II in healthy children.

Timeline

Start
2009-01
Primary completion
2009-10
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Varivax Vaccine 0.5 ml Other
Background Measles, Mumps, and Rubella Virus Vaccine Live (MMR) Vaccine 0.5 ml Other

Indications